Press release from Companies

Publicerat: 2019-12-12 15:05:00

Invent Medic Sweden AB: Correction: Invent Medic receives loans from Almi Företagspartner and the chairman of the board

In the previous press release the interest of the loan fom Lars Persson was omitted. The Interest  is set to 5% at a year basis. Invent Medic announces that the company has received a loan of 1.5 MSEK from Swedish state-owned Almi Företagspartner and a loan of 1.0 MSEK from the company’s chairman of the board. The loan from Almi has a duration of 60 months, and the loan from the chairman has a duration of 6 months. For both loans, interest rate will be paid at market terms.

The lenders of the loans to Invent Medic is Almi Företagspartner and the chairman of the board, and the company’s largest shareholder, Lars Persson.

“This financing shows that Invent Medic has a solid plan for the way forward, and that the board has full confidence in our ongoing expansion phase in Europe with Efemia bladder support that will be followed by the United States. We now have the capital needed to operate the company during the ongoing launches of Efemia in Norway, the UK and Germany and in Belgium and the Netherlands in the beginning of 2020. Invent Medic will then have a substantial market presence in Europe, which makes the company even more attractive for potential partners and investors, says Invent Medic’s CEO Karin Bryder. 

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

This information is information that Invent Medic Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on December 12, 2019.

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.

Läs mer hos Cision
Läs mer om Invent Medic Sweden AB